| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $13,174,369 | 16 | 100 |
| Grossman Jerrold B | director | 0 | $0 | 1 | $213,100 | $-213,100 |
| Guiheen Lawrence P. | director | 0 | $0 | 3 | $601,836 | $-601,836 |
| Grossman Adam S | President and CEO | 0 | $0 | 9 | $3.53M | $-3.53M |
| ELMS STEVE | director | 0 | $0 | 3 | $8.83M | $-8.83M |
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Over the last 12 months, insiders at ADMA Biologics, Inc. have bought $0 and sold $13.17M worth of ADMA Biologics, Inc. stock.
On average, over the past 5 years, insiders at ADMA Biologics, Inc. have bought $421,781 and sold $13.65M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 130,000 shares for transaction amount of $482,144 was made by Grossman Jerrold B (director) on 2023‑08‑30.
| 2025-12-15 | Sale | Grossman Adam S | President and CEO | 21,000 0.0088% | $19.79 | $415,590 | -7.35% | |
| 2025-11-19 | Sale | Grossman Adam S | President and CEO | 21,000 0.0089% | $16.00 | $336,000 | +18.06% | |
| 2025-09-15 | Sale | Grossman Adam S | President and CEO | 21,000 0.0093% | $16.13 | $338,730 | +5.20% | |
| 2025-08-15 | Sale | Grossman Adam S | President and CEO | 21,000 0.0087% | $16.88 | $354,480 | -0.62% | |
| 2025-07-15 | Sale | Grossman Adam S | President and CEO | 21,000 0.0091% | $18.66 | $391,860 | -5.17% | |
| 2025-06-16 | Sale | Grossman Adam S | President and CEO | 21,000 0.009% | $20.81 | $437,010 | -15.36% | |
| 2025-06-16 | Sale | ELMS STEVE | director | 194,749 0.0809% | $20.24 | $3.94M | -15.36% | |
| 2025-06-13 | Sale | ELMS STEVE | director | 137,931 0.0578% | $20.82 | $2.87M | -16.99% | |
| 2025-06-12 | Sale | ELMS STEVE | director | 92,941 0.0391% | $21.69 | $2.02M | -19.97% | |
| 2025-06-09 | Sale | Grossman Jerrold B | director | 10,000 0.0043% | $21.31 | $213,100 | -17.06% | |
| 2025-06-09 | Sale | Guiheen Lawrence P. | director | 20,000 0.0084% | $20.96 | $419,200 | -17.06% | |
| 2025-05-22 | Sale | Guiheen Lawrence P. | director | 1,221 0.0005% | $20.12 | $24,567 | -13.12% | |
| 2025-05-21 | Sale | Guiheen Lawrence P. | director | 7,779 0.0033% | $20.32 | $158,069 | -12.57% | |
| 2025-05-15 | Sale | Grossman Adam S | President and CEO | 21,000 0.0089% | $19.45 | $408,450 | -8.33% | |
| 2025-04-15 | Sale | Grossman Adam S | President and CEO | 21,000 0.0103% | $21.46 | $450,660 | -19.28% | |
| 2025-03-19 | Sale | Grossman Adam S | President and CEO | 21,000 0.0082% | $18.92 | $397,320 | -11.98% | |
| 2024-11-22 | Sale | Grossman Adam S | President and CEO | 48,967 0.0205% | $21.10 | $1.03M | -16.90% | |
| 2024-11-22 | Sale | Tade Brad L. | CFO and Treasurer | 15,000 0.0063% | $21.15 | $317,250 | -16.90% | |
| 2024-09-09 | Sale | Guiheen Lawrence P. | director | 9,000 0.0039% | $18.47 | $166,189 | +0.30% | |
| 2024-08-30 | Sale | Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | 24,150 0.0101% | $16.90 | $408,050 | +6.53% |
| Grossman Adam S | President and CEO | 2007850 0.8436% | $33.59M | 37 | 16 | <0.0001% |
| Grossman Jerrold B | director | 478194 0.2009% | $8M | 17 | 2 | <0.0001% |
| Guiheen Lawrence P. | director | 94830 0.0398% | $1.59M | 5 | 4 | <0.0001% |
| ELMS STEVE | director | 87330 0.0367% | $1.46M | 0 | 8 | |
| PERCEPTIVE ADVISORS LLC | 10 percent owner | 13262375 5.5725% | $221.88M | 3 | 9 | <0.0001% |
| Biotest Divestiture Trust | 10 percent owner | 4295580 1.8049% | $71.87M | 0 | 2 | |
| Aisling Capital II LP | 10 percent owner | 3620143 1.5211% | $60.56M | 1 | 0 | |
| Burrill Capital Fund IV, L.P. | 10 percent owner | 1433304 0.6022% | $23.98M | 1 | 0 | |
| LENZ BRIAN | EVP, CFO | 782013 0.3286% | $13.08M | 15 | 2 | +5.59% |
| Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | 449088 0.1887% | $7.51M | 0 | 1 | |
| KWON YOUNG | director | 241441 0.1014% | $4.04M | 2 | 1 | +48.43% |
| Tade Brad L. | CFO and Treasurer | 199433 0.0838% | $3.34M | 0 | 1 | |
| Mond James | EVP, CSO and CMO | 73174 0.0307% | $1.22M | 8 | 0 | +2.83% |
| RICHMAN ERIC I | director | 36530 0.0153% | $611,146.90 | 3 | 0 | +39.74% |
| DEMSKI MARTHA J | director | 4200 0.0018% | $70,266.00 | 2 | 0 | <0.0001% |
| Fong Bryant | director | 0 0% | $0 | 0 | 1 | |
| Biotest AG | 10 percent owner | 0 0% | $0 | 1 | 1 | +103.33% |
$159,914,414 | 243 | 18.52% | $4.63B | |
$66,736,176 | 136 | 27.54% | $3.96B | |
$193,151,375 | 134 | 8.18% | $4.42B | |
ADMA Biologics, Inc. (ADMA) | $52,263,649 | 70 | 1.18% | $3.98B |
$224,382,625 | 44 | 27.62% | $4.87B | |
$104,428,685 | 44 | 22.55% | $3.53B | |
$148,770,544 | 34 | 80.63% | $3.33B | |
$1,275,975,557 | 32 | 19.44% | $4.54B | |
$150,253,463 | 26 | -52.83% | $3.4B | |
$3,073,199 | 10 | 16.77% | $5.09B | |
$35,908,794 | 10 | 126.31% | $5.2B | |
$1,248,715 | 10 | 5.66% | $3.34B | |
$25,064,843 | 9 | 12.75% | $4.52B | |
$1,711,150 | 9 | 31.59% | $3.64B | |
$182,500,000 | 6 | 29.00% | $3.91B | |
$2,246,813 | 6 | 70.15% | $4.95B | |
$461,215 | 5 | 10.35% | $3.78B | |
$50,990,767 | 2 | 19.79% | $3.84B | |
$7,600,000 | 1 | -4.05% | $4.34B |
| Increased Positions | 175 | +36.46% | 37M | +17.98% |
| Decreased Positions | 219 | -45.63% | 29M | -13.72% |
| New Positions | 68 | New | 29M | New |
| Sold Out Positions | 63 | Sold Out | 9M | Sold Out |
| Total Postitions | 436 | -9.17% | 217M | +4.26% |
| Blackrock, Inc. | $637,095.00 | 14.97% | 35.63M | -841,666 | -2.31% | 2025-09-30 |
| Vanguard Group Inc | $375,033.00 | 8.81% | 20.97M | -388,719 | -1.82% | 2025-09-30 |
| State Street Corp | $242,482.00 | 5.7% | 13.56M | +1M | +12.28% | 2025-09-30 |
| Invesco Ltd. | $223,598.00 | 5.25% | 12.51M | -312,663 | -2.44% | 2025-09-30 |
| Sachem Head Capital Management Lp | $160,205.00 | 3.77% | 8.96M | +9M | New | 2025-09-30 |
| Geode Capital Management, Llc | $103,950.00 | 2.44% | 5.81M | -99,383 | -1.68% | 2025-09-30 |
| Nuveen, Llc | $102,348.00 | 2.41% | 5.72M | +161,241 | +2.9% | 2025-09-30 |
| Westfield Capital Management Co Lp | $91,310.00 | 2.15% | 5.11M | +5M | New | 2025-09-30 |
| Dimensional Fund Advisors Lp | $85,793.00 | 2.02% | 4.8M | +35,199 | +0.74% | 2025-09-30 |
| American Century Companies Inc | $83,963.00 | 1.97% | 4.7M | +84,934 | +1.84% | 2025-09-30 |